---
title: "Changes in Microbiota in Type II diabetes"
author: 
  - "Anita Skovbjerg Hjort-Gregersen s201190"
  - "Asiya Mohamad Yusuf Muses 243930"
  - "Magnus Harthimmer s233426"
  - "Marco Andreis s243116"
  - "Rebecca Hjermind Millum s215024"
date: "December 3, 2024"
format:
  revealjs:
    transition: slide
    logo: "images/DTU_logo.png"
    theme: [simple, custom.scss]
self-contained: true 
footer: "R4BDS - Group 09"
---


## Humans as a complex ecosystems

::: columns

::: {.column width="60%"}
![](images/human_microbiota.png){fig-align="left" width="600"}
:::

::: {.column width="40%"}
::: {.fragment}
<a href="https://doi.org/10.1038/s41392-022-00974-4">
![](images/microbiota_paper.png){fig-align="bottom" width="100%" margin-bottom=0.5em}
</a>
![](images/microbiota_in_health_and_disease.png){fig-align="bottom" width="100%"}
:::
:::

:::

## Data set history
::: {style="display: flex; flex-direction: column; height: 25%; font-size: 35px"}
::: columns
::: {.column width="40%"}
8 shotgun sequencing metagenomics studies

:::

::: {.column width="30%"}
Merged into a single dataset
:::

::: {.column width="30%"}
Uploaded on Kaggle as CSV
:::
:::
:::

::: {style="display: flex; flex-direction: column; height: 75%;"}
![](images/dataset_history.png){width="100%"}
:::

## Data selection

::: columns
::: {.column width="30%"}
Using the **whole** dataset?



Focusing only on **one** study?
:::

::: {.column width="70%"}
![](../results/04_valid_entries.jpg){width="1200"}
:::
:::

## The WT2D dataset
::: {.columns}
::: {.column width="50%"}



::: {style="font-size: 35px; margin-bottom: 40px"}
What is glucose tolerance?
::: 
![](images/WT2D.png){fig-align="left" width="800"}
:::

::: {.column width="50%"}

::: {style="font-size: 35px; margin-top: 60px"}
![](../results/07_distribution_of_sample_by_glucose_tolerance.jpg){width="500"}
:::
:::
:::

## Hallmarks of Diabetes

::: columns
::: {.column width="33.3%"}
::: {style="font-size: 0.6em; font-weight: bold;"}
HDL ("Good Cholesterol")
:::

![](../results/07_ridges_hdl_vs_glucose_tolerance.jpg){width="400"}

::: {style="font-size: 0.6em;"}
-   **Lower in Type 2 Diabetes**
-   **Risk:** Heart disease, stroke
-   **Factors:** Medications, overweight
-   **Distribution:** Shift to lower values
:::
:::

::: {.column width="33.3%"}
::: {style="font-size: 0.6em; font-weight: bold;"}
Hemoglobin A1C
:::

![](../results/07_hba1c_vs_glucose_tolerance.jpg){width="400"} 

::: {style="font-size: 0.5em;"}
-   **Measures:** Avg. glucose (10â€“12 weeks)
-   **Threshold:** \>48 mmol/mol = Type 2 Diabetes
-   **Findings:** 12.41% of Type 2 Diabetes cases above threshold
:::
:::

::: {.column width="33.3%"}
::: {style="font-size: 0.6em; font-weight: bold;"}
BMI
:::

![](../results/07_bmi_vs_glucose_tolerance.jpg){width="400"}

::: {style="font-size: 0.6em;"}
-   **Not Significant**
-   **Waist Circumference:** Strong correlation
:::
:::
:::

## Hallmark of [*Type 2*]{.underline} Diabetes

::: columns
::: {.column width="33.3%"}
::: {style="font-size: 0.6em; font-weight: bold;"}
GAD-Antibodies
:::

![](../results/07_gad_ab_vs_bmi_glucose_tolerance.jpg){width="400"}

::: {style="font-size: 0.6em;"}
-   **Associated with Type 1 Diabetes**
-   **Not significant across BMI or glucose tolerance classes**
:::
:::

::: {.column width="33.3%"}
::: {style="font-size: 0.6em; font-weight: bold;"}
C-Peptide
:::

![](../results/07_c_peptide_vs_bmi_glucose_tolerance.jpg){width="400"}

::: {style="font-size: 0.6em;"}
-   **Marker for insulin production**
-   **Higher in Type 2 Diabetes**
:::
:::

::: {.column width="33.3%"}
::: {style="font-size: 0.6em; font-weight: bold;"}
Fasting Insulin
:::

![](../results/07_fasting_insuling_vs_glucose_tolerance_bar.jpg){width="400"}

::: {style="font-size: 0.6em;"}
-   **Higher in Type 2 Diabetes**
-   **Statistically significant parameter**
:::
:::
:::

::: notes
-   Type 1 and type 2 diabetes are similar in the features showed before, but very different in other characteristics

-   lets have a look at GAD antibodies, C-peptide and fasting insulin levels

### GAD Antibodies Notes

- GAD (Glutamic Acid Decarboxylase) antibodies with glucose tolerance grouped by BMI
- not statistically significant in our analysis of type 2 diabetes
- typically associated with type 1 diabetes. (autoimmunity target GAD and beta cell of pancreas)
- Same for the BMI classes (hence not relevant in type 2 diabetes)

Relevant image: `07_gad_ab_vs_bmi_glucose_tolerance.jpg`

### C-Peptide Notes

- C-peptide concentration with glucose tolerance grouped by BMI
- C-peptide differentiate t1 and t2 diabetes since it is cleaved during insulin production (insulin is only produced in t2)
- Higher levels of C-peptide in type 2 diabetes patients indicate that the body is producing more insulin to compensate for elevated blood sugar levels.
- obese produce more due to increased insulin resistance

% C-peptide is a 31-amino-acid sequence that connects the A and B chains of proinsulin. 
Relevant image: `07_c_peptide_vs_bmi_glucose_tolerance.jpg`

### Fasting Insulin Notes

- fasting insulin levels for each glucose tolerance group
- t2 diabetes have higher levels of fasting insulin due to insulin resistance
- statistically significant parameter.

Relevant image: `07_fasting_insuling_vs_glucose_tolerance_bar.jpg`
:::


## Statins and diabetes

::: columns
::: {.column width="50%"}
![](../results/07_statins_cholesterol.jpg){width="500"}

::: {style="font-size: 0.6em;"}
-   **Used as cardiovascular disease treatment**
-   **Lower cholesterol levels**
:::
:::


::: {.column width="50%"}
![](../results/07_linear_fasting_insuline_cholesterol.jpg){width="500"}

::: {style="font-size: 0.6em;"}
-   **Insulin levels are not affected by statin**
-   **Lowers colesterol levels**
-   **Statins not directly linked to type 2 diabetes**

:::
:::
:::

::: notes
### Statin Notes
- Cholesterol level for each glucose tolerance group, grouped by on statins yes/no
- Statins inhibit an enzyme essential for cholesterol production in the liver 
- Statins reduce the risk of cardiovascular related events such as heart attack, stroke, and death due to CVD.
- regardless the glucose tolerance
% - Statins inhibit the enzyme HMG-CoA reductase, 

### inuslin Notes
-  fasting insulin is not affected by statin, 
- but cholesterol level is lowered by statin
- Hence statins are no diabetes medication
:::

## Relative abundance data {style="font-size:40px"}

::: columns
::: {.column width="50%"}
![](images/MetaPhlAn2.png){width="110%"}
<a href="https://www.france-genomique.org/expertises-technologiques/metagenomique/metagenomique-shotgun/">
  ![France genomique](images/shotgun.jpg){width="110%"}
</a>
:::

::: {.column width="50%"}
::: {style="font-size: 0.6em;"}
Are there differences between healthy and diseased?
:::
![](../results/08_most_different_species.jpg){width="600"}
:::
:::

## Are there really differences? {style="font-size:40px"}

::: columns
::: {.column width="50%"}
![](../results/10_pca_glucose_tolerance.jpg){width="500"}
:::

::: {.column width="50%"}
![](../results/08_species_heatmap.jpg){width="500"}
:::
:::

## Conclusions

::: columns
::: {.column width="50%"}
![](../results/10_sig_diff_species.jpg){width="500"}
:::

::: {.column width="50%"}
:::fragment
<a href="https://doi.org/10.1038/nature12198">
  ![](images/WT2D_paper.png){width="110%"}
</a>
![](images/Clostridium_confirmation.png){width="500"}
:::

:::
:::